AGC Biologics Commits Half of New Yokohama Biomanufacturing Plant to Major Long-Term Deal

August 9, 2026

Megaproject Japan

Overview

AGC Biologics has secured a significant multi-million dollar, long-term commercial manufacturing contract with an undisclosed pharmaceutical firm for its new Yokohama facility, set to open in 2027. This landmark agreement will dedicate approximately half of the plant’s 18,000-liter single-use mammalian bioreactor capacity. The deal underscores AGC Biologics’ strategic expansion and Japan’s strengthening position in the global biopharmaceutical supply chain, backed by government support.

In Depth

Background

The global biopharmaceutical market is experiencing rapid growth, fueled by innovative modalities such as cell and gene therapies, alongside advanced mRNA technologies. This expansion necessitates sophisticated manufacturing expertise and substantial production capacity to meet escalating worldwide demand. Japan’s Ministry of Economy, Trade and Industry (METI) has provided significant support for this project, signaling the government’s strategic focus on bolstering domestic competitiveness and ensuring stable supply chains within biopharmaceutical manufacturing. As a leading global Contract Development and Manufacturing Organization (CDMO), AGC Biologics maintains a robust international presence across North America, Europe, and Asia; this latest substantial contract in Japan is poised to further enhance its global footprint and strategic capabilities.

Key Findings

AGC Biologics has officially announced a multi-million dollar, long-term commercial manufacturing agreement with an undisclosed pharmaceutical company. This landmark deal pertains to its state-of-the-art facility currently under construction in Yokohama, Japan. This strategic agreement will secure approximately half of the new facility’s mammalian manufacturing capacity. Expected to commence operations in 2027, the Yokohama plant will boast a total of 18,000 liters of single-use bioreactor capacity, with this long-term commitment ensuring stable operations and strategically positioning AGC Biologics within the rapidly expanding global biopharmaceutical market.

Beyond traditional drug substance (DS) manufacturing, the new Yokohama facility is engineered to offer comprehensive contract manufacturing services for advanced modalities, including cell therapies and mRNA vaccines/therapeutics. This expansive service portfolio significantly bolsters AGC Biologics’ standing as a versatile CDMO capable of supporting a diverse range of biopharmaceutical innovations. The facility’s reliance on cutting-edge single-use bioreactor technology offers several advantages, including a reduced risk of cross-contamination between batches, accelerated changeovers, and enhanced flexibility for production scale-up. These technological attributes are critical for efficiently addressing diverse client requirements, ranging from small-batch multi-product campaigns to large-scale commercial manufacturing.

The Yokohama facility is strategically targeting regulatory approvals from key global agencies, including Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (UK MHRA). Achieving these approvals will allow products manufactured at the site to serve major markets worldwide, further cementing Japan’s international reputation as a pivotal biopharmaceutical manufacturing hub. This foundational contract marks a crucial milestone in strengthening AGC Biologics’ business infrastructure and is expected to significantly accelerate its future growth trajectory.

Source: https://www.megaproject.com/news/factory/agc-bio-nabs-manufacturing-deal-for-japan-site-worth-hundreds-of-millions

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.